BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jazz Pharmaceuticals, Inc. (JAZZ) Announces New Executive Appointments


1/25/2012 6:49:03 AM

DUBLIN, Jan. 24, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced several senior management appointments that will strengthen and broaden the company's leadership team.

The appointments include:

  • Suzanne Sawochka Hooper will join the company and will serve as general counsel and an executive officer following the upcoming retirement of Carol Gamble in March. Ms. Hooper is currently a partner at Cooley LLP, where she has practiced corporate and securities law since 1996. She has provided counsel to Jazz Pharmaceuticals for more than five years and was closely involved in the company's recent business combination with Azur Pharma. She will be based in the Palo Alto office.
  • Fintan Keegan becomes senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations. Mr. Keegan was previously with Azur Pharma since 2006. He has over 27 years of experience in manufacturing and related technical operations and will be based in the Dublin headquarters.
  • Eunan Maguire becomes senior vice president of strategy and corporate development, where he will focus on the company's efforts to further expand its product portfolio. Mr. Maguire was a co-founder of Azur Pharma and was president of US operations, where he was responsible for commercial, medical, legal and administrative activities in the US. He has over 15 years of industry experience and will be based in the Philadelphia office.

Additional members of the company's senior management team include: Russell Cox, senior vice president and chief commercial officer; Kathryn Falberg, senior vice president and chief financial officer; Jeffrey Tobias, M.D., senior vice president of research and development and chief medical officer; Heather McGaughey, vice president of human resources; and Robert McKague, vice president and chief compliance officer.

"One of our most important assets is our people, and I am thrilled to be working with a smart, strategic group, who not only have the capability, but also the passion to build Jazz Pharmaceuticals plc for the long term. This team has the right skills and industry experience to drive continued success and address unmet medical needs of patients," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "I would also like to acknowledge Carol Gamble for her many important contributions to the company during the past nine years and her tremendous commitment to patients and to our mission."

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health. The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).

SOURCE Jazz Pharmaceuticals plc



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES